Advanced practice providers have the opportunity to instill hope in patients through education and personalized care.

Relacorilant plus nab-paclitaxel improved PFS and showed a trend toward longer OS in platinum-resistant ovarian cancer in ROSELLA.

An oral tablet formulation of zanubrutinib was approved for use in patients with certain lymphomas or leukemia and ...

UGN-102 has received FDA approval for use in patients with low-grade intermediate-risk non-muscle-invasive bladder cancer.

Education before subcutaneous daratumumab administration can both reassure patients and reduce the occurrence of adverse ...

Toxicities related to Teliso-V are manageable for patients with c-Met overexpressing non-small cell lung cancer, according to ...

Oncology nurses and APPs can help reduce discrimination faced by patients with cancer who are members of the LGBTQIA+ ...

A molecular assay identified patients with non–small cell lung cancer most likely to benefit from adjuvant chemotherapy, ...

Retifanlimab-dlwr (Zynyz) was granted approval from the FDA for treatment of locally recurrent or metastatic squamous cell ...

Tarlatamab prolonged both overall and progression-free survival in the treatment of small cell lung cancer, backing it as a ...

The FDA approved darolutamide monotherapy for use in metastatic hormone-sensitive prostate cancer following ARANOTE findings.

Panelists discuss how real-world data from the San Antonio Breast Cancer Symposium demonstrated that elacestrant's ...